Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Vijaya Ramesh, Ph.D.

Co-Author

This page shows the publications co-authored by Vijaya Ramesh and James Gusella.
Connection Strength

3.104
  1. mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. J Biol Chem. 2021 Jan-Jun; 296:100157.
    View in: PubMed
    Score: 0.237
  2. mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. J Biol Chem. 2020 Dec 09; 296:100157.
    View in: PubMed
    Score: 0.237
  3. Mediator Subunit Med28 Is Essential for Mouse Peri-Implantation Development and Pluripotency. PLoS One. 2015; 10(10):e0140192.
    View in: PubMed
    Score: 0.166
  4. A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. Oncotarget. 2015 Jul 10; 6(19):16981-97.
    View in: PubMed
    Score: 0.163
  5. Lack of association of rare functional variants in TSC1/TSC2 genes with autism spectrum disorder. Mol Autism. 2013 Mar 20; 4(1):5.
    View in: PubMed
    Score: 0.139
  6. Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types. Mol Cancer Res. 2012 May; 10(5):649-59.
    View in: PubMed
    Score: 0.129
  7. Mapping of ornithine aminotransferase gene sequences to mouse chromosomes 7, X, and 3. Mamm Genome. 1992; 3(1):17-22.
    View in: PubMed
    Score: 0.128
  8. Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas. BMC Med Genomics. 2009 Jul 09; 2:42.
    View in: PubMed
    Score: 0.107
  9. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol. 2009 Aug; 29(15):4250-61.
    View in: PubMed
    Score: 0.106
  10. Molecular basis of ornithine aminotransferase deficiency in B-6-responsive and -nonresponsive forms of gyrate atrophy. Proc Natl Acad Sci U S A. 1988 Jun; 85(11):3777-80.
    View in: PubMed
    Score: 0.100
  11. The ornithine aminotransferase (OAT) locus: analysis of RFLPs in gyrate atrophy. Am J Hum Genet. 1988 Feb; 42(2):365-72.
    View in: PubMed
    Score: 0.097
  12. Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth. Neurobiol Dis. 2008 Feb; 29(2):278-92.
    View in: PubMed
    Score: 0.095
  13. Mediator subunit MED28 (Magicin) is a repressor of smooth muscle cell differentiation. J Biol Chem. 2007 Nov 02; 282(44):32152-7.
    View in: PubMed
    Score: 0.095
  14. Localization of the ornithine aminotransferase gene and related sequences on two human chromosomes. Hum Genet. 1987 Jun; 76(2):121-6.
    View in: PubMed
    Score: 0.093
  15. Investigation of gyrate atrophy using a cDNA clone for human ornithine aminotransferase. DNA. 1986 Dec; 5(6):493-501.
    View in: PubMed
    Score: 0.090
  16. Magicin associates with the Src-family kinases and is phosphorylated upon CD3 stimulation. Biochem Biophys Res Commun. 2006 Sep 29; 348(3):826-31.
    View in: PubMed
    Score: 0.088
  17. The NF2 tumor suppressor Merlin and the ERM proteins interact with N-WASP and regulate its actin polymerization function. J Biol Chem. 2005 Apr 01; 280(13):12517-22.
    View in: PubMed
    Score: 0.079
  18. Magicin, a novel cytoskeletal protein associates with the NF2 tumor suppressor merlin and Grb2. Oncogene. 2004 Nov 18; 23(54):8815-25.
    View in: PubMed
    Score: 0.078
  19. Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. PLoS One. 2021; 16(7):e0252048.
    View in: PubMed
    Score: 0.062
  20. Interdomain interaction of merlin isoforms and its influence on intermolecular binding to NHE-RF. J Biol Chem. 1999 Nov 26; 274(48):34438-42.
    View in: PubMed
    Score: 0.055
  21. Merlin: the neurofibromatosis 2 tumor suppressor. Biochim Biophys Acta. 1999 Mar 25; 1423(2):M29-36.
    View in: PubMed
    Score: 0.053
  22. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. Neuro Oncol. 2018 08 02; 20(9):1185-1196.
    View in: PubMed
    Score: 0.050
  23. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. PLoS One. 2018; 13(6):e0197350.
    View in: PubMed
    Score: 0.050
  24. Pain correlates with germline mutation in schwannomatosis. Medicine (Baltimore). 2018 Feb; 97(5):e9717.
    View in: PubMed
    Score: 0.049
  25. NHE-RF, a regulatory cofactor for Na(+)-H+ exchange, is a common interactor for merlin and ERM (MERM) proteins. J Biol Chem. 1998 Jan 16; 273(3):1273-6.
    View in: PubMed
    Score: 0.049
  26. The merlin tumor suppressor localizes preferentially in membrane ruffles. Oncogene. 1996 Sep 19; 13(6):1239-47.
    View in: PubMed
    Score: 0.044
  27. Frequency and distribution of NF2 mutations in schwannomas. Genes Chromosomes Cancer. 1996 Sep; 17(1):45-55.
    View in: PubMed
    Score: 0.044
  28. Neurofibromatosis 2: loss of merlin's protective spell. Curr Opin Genet Dev. 1996 Feb; 6(1):87-92.
    View in: PubMed
    Score: 0.042
  29. Neurofibromatosis 2 gene in human colorectal cancer. Cancer Genet Cytogenet. 1995 Oct 01; 84(1):24-6.
    View in: PubMed
    Score: 0.041
  30. Neuropathology and molecular genetics of neurofibromatosis 2 and related tumors. Brain Pathol. 1995 Apr; 5(2):163-72.
    View in: PubMed
    Score: 0.040
  31. The murine NF2 homologue encodes a highly conserved merlin protein with alternative forms. Hum Mol Genet. 1994 Mar; 3(3):407-11.
    View in: PubMed
    Score: 0.037
  32. DNA diagnosis of neurofibromatosis 2. Altered coding sequence of the merlin tumor suppressor in an extended pedigree. JAMA. 1993 Nov 17; 270(19):2316-20.
    View in: PubMed
    Score: 0.036
  33. A 15-bp deletion in exon 5 of the ornithine aminotransferase (OAT) locus associated with gyrate atrophy. Hum Mutat. 1992; 1(4):293-7.
    View in: PubMed
    Score: 0.032
  34. Molecular pathology of gyrate atrophy of the choroid and retina due to ornithine aminotransferase deficiency. Mol Biol Med. 1991 Feb; 8(1):81-93.
    View in: PubMed
    Score: 0.030
  35. Splicing defect at the ornithine aminotransferase (OAT) locus in gyrate atrophy. Am J Hum Genet. 1990 Nov; 47(5):790-4.
    View in: PubMed
    Score: 0.029
  36. Inactivation patterns of NF2 and DAL-1/4.1B (EPB41L3) in sporadic meningioma. Cancer Genet Cytogenet. 2005 Oct 15; 162(2):135-9.
    View in: PubMed
    Score: 0.021
  37. A region of deletion on chromosome 22q13 is common to human breast and colorectal cancers. Cancer Res. 2000 Jun 01; 60(11):2836-9.
    View in: PubMed
    Score: 0.014
  38. Mapping of a target region of allelic loss to a 0.5-cM interval on chromosome 22q13 in human colorectal cancer. Gastroenterology. 1999 Oct; 117(4):831-7.
    View in: PubMed
    Score: 0.014
  39. Loss of the NF2 gene and merlin occur by the tumorlet stage of schwannoma development in neurofibromatosis 2. J Neuropathol Exp Neurol. 1998 Dec; 57(12):1164-7.
    View in: PubMed
    Score: 0.013
  40. The NF2 gene and merlin protein in human osteosarcomas. Neurogenetics. 1998 Dec; 2(1):73-4.
    View in: PubMed
    Score: 0.013
  41. Universal absence of merlin, but not other ERM family members, in schwannomas. Am J Pathol. 1997 Dec; 151(6):1649-54.
    View in: PubMed
    Score: 0.012
  42. Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. Am J Pathol. 1995 Apr; 146(4):827-32.
    View in: PubMed
    Score: 0.010
  43. Evidence for subarachnoid spread in the development of multiple meningiomas. Brain Pathol. 1995 Jan; 5(1):11-4.
    View in: PubMed
    Score: 0.010
  44. MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. Hum Mol Genet. 1994 Oct; 3(10):1841-5.
    View in: PubMed
    Score: 0.010
  45. Analysis of the neurofibromatosis 2 gene in human ependymomas and astrocytomas. Cancer Res. 1994 Jan 01; 54(1):45-7.
    View in: PubMed
    Score: 0.009
  46. Chromosomal localization of the gene for human B-cell antigen CD40. Somat Cell Mol Genet. 1993 May; 19(3):295-8.
    View in: PubMed
    Score: 0.009
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.